Starling Oncology director Brad Hively to step down as vice chairman, not seek re-election in 2027
STLN•Board and committee changes
- Starling Oncology director Brad Hively will not stand for re-election at the 2027 annual stockholders meeting.
- He will remain on the board until the meeting.
- Effective immediately, Hively stepped down as vice chairman.
- He also left the compliance committee, ending all committee roles.
